Propafenone Initiation Guidelines

Initial Dose and Patient Selection

• The American College of Cardiology and European Heart Society recommend that the first dose of propafenone must be given in a monitored hospital setting to establish safety before any outpatient use is permitted, in order to assess for bradycardia, proarrhythmic effects, and to confirm the patient can tolerate the medication safely 1, 2, 4, 5
• The American College of Cardiology recommends that patients with structural heart disease, including left ventricular dysfunction or reduced ejection fraction, are contraindicated for propafenone initiation 1, 2
• The European Heart Society recommends that patients with sinus or AV node dysfunction, bundle branch block, or QT interval prolongation should not be initiated on propafenone 1, 2
• The American Heart Association recommends that patients with Brugada syndrome should not be initiated on propafenone as it can unmask this condition and cause sudden death 1, 4
• The American College of Cardiology recommends that patients with lone atrial fibrillation without structural heart disease can be initiated as outpatients after successful in-hospital trial 1, 2

Mandatory Pre-Treatment Requirements

• The American College of Cardiology and European Heart Society recommend that a beta-blocker or non-dihydropyridine calcium channel blocker must be given at least 30 minutes before propafenone administration to prevent rapid 1:1 AV conduction if atrial flutter develops during treatment 1, 2, 4, 6

Dosing Regimens

• The American College of Cardiology recommends a single oral dose of 450-600 mg for cardioversion of paroxysmal atrial fibrillation, with a mean time to conversion of approximately 2 hours and efficacy rates of 72-78% within 8 hours and up to 94% overall success 3

Monitoring During Initiation

• The American Heart Association recommends continuous ECG monitoring for at least 8 hours after first dose and assessment for bradycardia at conversion from AF to sinus rhythm 1, 4
• The European Heart Society recommends PR interval monitoring and QRS duration monitoring during propafenone initiation 7

Critical Safety Warnings

• The American College of Cardiology and European Heart Society recommend that propafenone can cause transformation to atrial flutter with rapid ventricular response, necessitating pre-treatment with AV nodal blocking agents 1, 4
• The American Heart Association recommends that proarrhythmic risk is higher in females 1, 4
• The European Heart Society recommends that propafenone can cause negative inotropic effects, requiring systematic exclusion of patients with left ventricular dysfunction 4, 6